Skip to content
Clinical Trials – home
Verifiedinfo

Suomen Terveystalo Oy

Finland Rautatienkatu 27, 33100 Tampere, Finland

  • Hidradenitis · Dermatitis atopic · Type 2 diabetes mellitus
  • Adults and children

About Specializations

Suomen Terveystalo Oy in Tampere, Finland specialises in clinical trials of conditions such as Hidradenitis, Dermatitis atopic, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Skin, Allergy, and Immune-Mediated Disease Research

At Suomen Terveystalo Oy in Tampere, clinical trials in dermatology and allergology focus on skin and connective tissue diseases as well as immune system diseases. The studies are exploring new treatment options and longer-term care strategies for inflammatory skin conditions and allergy-related disorders.

  • Atopic dermatitis and prurigo nodularis research is assessing whether newer therapies can better reduce itch and improve symptom control.
  • Hidradenitis suppurativa and Netherton syndrome trials are evaluating treatment effectiveness and safety in difficult-to-manage skin disease.
  • Birch pollen-induced allergic rhinoconjunctivitis studies are testing whether allergy treatment can ease seasonal symptoms and reduce rescue medication use.
  • Plaque psoriasis research is examining long-term tolerability and sustained benefit of advanced therapy.

These studies reflect a strong focus on improving care for chronic inflammatory conditions and allergic disease, with attention to both symptom relief and long-term safety.

Neurology and Migraine Studies

The site also supports research in nervous system diseases, with trials centered on multiple sclerosis and migraine. The main goal is to improve prevention, acute treatment, and long-term treatment safety for people living with these recurring neurological conditions.

  • Multiple sclerosis and relapsing multiple sclerosis studies are looking at longer-term safety and ongoing treatment benefit.
  • Chronic migraine and migraine attacks with or without aura trials are evaluating both prevention and symptom relief.
  • Research in this area is helping clarify which therapies may offer better control for patients who have not responded well to earlier treatments.

Overall, the neurological portfolio at Suomen Terveystalo Oy emphasizes practical improvements in daily functioning, symptom reduction, and treatment durability.

Metabolic and Cardiovascular Research

Clinical trials in nutritional and metabolic diseases and cardiovascular diseases are examining treatment approaches for type 2 diabetes, hypertension, and broader cardiovascular disease. These studies aim to strengthen disease control and lower the risk of serious complications.

  • Type 2 diabetes research is testing whether newer treatment combinations can improve blood sugar control.
  • Hypertension and cardiovascular disease studies are evaluating whether therapy can reduce major heart-related events.
  • These trials are designed to better understand how treatments may support both metabolic health and cardiovascular protection.

The research here adds an important internal medicine dimension to the site’s portfolio, linking chronic disease management with prevention of long-term complications.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Rautatienkatu 2733100 TampereFinland
Recruiting now
no trials
Conditions studied
3
Partner status
Verified

More sites in TampereFinland

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

6 clinical trials

Dermatitis atopic

Not recruiting
Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hidradenitis

Not recruiting
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Dermatitis atopic

Not recruiting
Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.